• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Raptiva Off and Running

Article

San Francisco - A study on Raptiva (efalizumab) shows patients with moderate-to-severe plaque psoriasis who received 12 weeks of treatment experienced a significant reduction in signs and symptoms, and patients who continued treatment to 24 weeks continued to benefit.

Related Videos
Related Content
Biologic Therapy Linked to Increased Density of Demodex Mites and Prevalence of Demodicosis in Patients With Psoriasis vs Controls

Biologic Therapy Linked to Increased Density of Demodex Mites and Prevalence of Demodicosis in Patients With Psoriasis vs Controls

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Patients With Hidradenitis Suppurativa Have Increased Odds of Respiratory Disease, According to Study Findings

Patients With Hidradenitis Suppurativa Have Increased Odds of Respiratory Disease, According to Study Findings

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Article
Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Article
© 2024 MJH Life Sciences

All rights reserved.